Published in Cancer Res on February 15, 1996
Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther (2005) 1.33
Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs (1997) 0.99
Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA. Br J Cancer (1999) 0.93
Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis (1997) 0.92
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax (1999) 0.90
Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs (1999) 0.88
Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer. PLoS One (2012) 0.86
Vaccines targeting the neovasculature of tumors. Vasc Cell (2011) 0.84
Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors. Clin Exp Metastasis (1999) 0.84
PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br J Cancer (1999) 0.79
Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11. Clin Exp Metastasis (2002) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J (1987) 4.56
Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature (1985) 3.97
Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem J (1986) 3.31
TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett (1998) 3.04
Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J (1987) 2.54
Oxymetry deep in tissues with low-frequency electron paramagnetic resonance. Proc Natl Acad Sci U S A (1994) 2.53
The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol (1992) 2.19
A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol (1997) 2.13
A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol (1992) 2.10
Overexpression of metallothionein confers resistance to anticancer drugs. Science (1988) 2.03
The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett (2000) 2.03
Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res (1981) 1.91
The role of the C-terminal domain in collagenase and stromelysin specificity. J Biol Chem (1992) 1.85
Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem (1998) 1.65
Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A (1993) 1.63
Elevated plasma stromelysin levels in arthritis. J Rheumatol (1994) 1.54
The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J (1992) 1.49
Retracted A phase I-II trial of cisplatin, hyperthermia and radiation in patients with locally advanced malignancies. Int J Radiat Oncol Biol Phys (1989) 1.43
Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J (1995) 1.41
The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry (1991) 1.41
Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas. Oncogene (2007) 1.40
PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest. Blood (1999) 1.36
The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry (1993) 1.36
Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem (1994) 1.34
Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta (1991) 1.28
Purification and characterization of human 72-kDa gelatinase (type IV collagenase). Use of immunolocalisation to demonstrate the non-coordinate regulation of the 72-kDa and 95-kDa gelatinases by human fibroblasts. Biol Chem Hoppe Seyler (1991) 1.24
The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol (1980) 1.24
Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J Biol Chem (1994) 1.23
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res (1987) 1.23
Measurement of differences in pO2 in response to perfluorocarbon/carbogen in FSa and NFSa murine fibrosarcomas with low-frequency electron paramagnetic resonance oximetry. Radiat Res (1996) 1.21
Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1 )integrin, leading to a marked induction of fibroblast cell motility. J Cell Sci (2000) 1.21
Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci (1999) 1.20
BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood (2000) 1.19
Metalloproteinases and tissue damage. Br J Rheumatol (1991) 1.18
Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family. Biochemistry (1994) 1.18
Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp (1998) 1.18
Diminished aqueous microviscosity of tumors in murine models measured with in vivo radiofrequency electron paramagnetic resonance. Cancer Res (1999) 1.16
Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res (1986) 1.15
Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions. Proc Natl Acad Sci U S A (1989) 1.14
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs (1997) 1.12
Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res (1981) 1.12
The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci (1994) 1.10
Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res (1988) 1.10
Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med (1986) 1.06
Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J (1999) 1.05
Molecular cloning and nucleotide sequence of rat lingual lipase cDNA. Nucleic Acids Res (1985) 1.03
Kupffer cell-derived 95-kd type IV collagenase/gelatinase B: characterization and expression in cultured cells. Hepatology (1995) 1.03
CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. J Clin Invest (1992) 1.03
Restriction fragment length polymorphism analysis and assignment of the metalloproteinases stromelysin and collagenase to the long arm of chromosome 11. Genomics (1988) 1.02
Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol (1991) 1.02
CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J Clin Invest (1993) 1.02
Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J Biol Chem (1998) 1.01
Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem (1990) 1.00
Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood (1993) 1.00
Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix (1990) 0.99
Gelatinase A (MMP-2) and cysteine proteinases are essential for the degradation of collagen in soft connective tissue. Matrix Biol (1998) 0.99
Mutation of the active site glutamic acid of human gelatinase A: effects on latency, catalysis, and the binding of tissue inhibitor of metalloproteinases-1. Biochemistry (1994) 0.98
Human progelatinase A can be activated by autolysis at a rate that is concentration-dependent and enhanced by heparin bound to the C-terminal domain. Eur J Biochem (1993) 0.98
Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. J Natl Cancer Inst (1992) 0.98
Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. Int J Hyperthermia (2001) 0.96
Cyclooxygenase and lipoxygenase inhibitors in cancer therapy. Prostaglandins Leukot Essent Fatty Acids (1996) 0.96
Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol (2000) 0.95
The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function. FEBS Lett (1996) 0.95
A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res (1991) 0.94
Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood (1996) 0.94
Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements. Blood (1995) 0.94
A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol (1990) 0.94
Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase. Biochem J (1995) 0.94
Metalloproteinase domain structure, cellular invasion and metastasis. Biochem Soc Trans (1994) 0.93
Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-beta levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int J Radiat Oncol Biol Phys (1997) 0.93
Active gelatinase B is identified by histozymography in the cartilage resorption sites of developing long bones. Dev Dyn (1999) 0.93
Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker. J Surg Oncol (1997) 0.93
Interaction of immunoactive monokines (interleukin 1 and tumor necrosis factor) in the bivalve mollusc Mytilus edulis. Proc Natl Acad Sci U S A (1990) 0.93
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol (1998) 0.92
Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis. FEBS Lett (1997) 0.92
Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis (1997) 0.92
CD10/NEP is expressed on Thy-1low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis. Blood (1992) 0.92
Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer (1995) 0.91
Murine common acute lymphoblastic leukemia antigen (CD10 neutral endopeptidase 24.11). Molecular characterization, chromosomal localization, and modeling of the active site. J Immunol (1992) 0.91
The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures. Cancer Res (2000) 0.91
Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol (2000) 0.91
Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A. Biochemistry (1994) 0.90
Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res (1995) 0.90
Collagen breakdown in soft connective tissue explants is associated with the level of active gelatinase A (MMP-2) but not with collagenase. Matrix Biol (1999) 0.90
CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase. Blood (1996) 0.89
Spectrum of cis-diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cells. Mol Carcinog (1991) 0.89
Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. J Rheumatol (1999) 0.89
CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. J Clin Invest (1994) 0.88
Matrix metalloproteinase inhibitors block osteoclastic resorption of calvarial bone but not the resorption of long bone. Ann N Y Acad Sci (1999) 0.88
Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases. Biochemistry (1992) 0.88
Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance. Cancer Res (1989) 0.88
Reciprocated matrix metalloproteinase activation: a process performed by interstitial collagenase and progelatinase A. Biochemistry (1994) 0.88
Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hyperthermia (1988) 0.88
Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol (1993) 0.88
Radiosensitization of EMT6 cells by four platinum complexes. Int J Radiat Oncol Biol Phys (1985) 0.87
Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr Pharm Des (2001) 0.87